Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
Description: Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company?s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||34.71%||Sales Growth - Q/Q||7.09%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-25.97%||ROE||-27.65%||ROI|
|Current Ratio||10.78||Quick Ratio||Long Term Debt/Equity||Debt Ratio||0.06|
|Gross Margin||Operating Margin||-1578.72%||Net Profit Margin||-1582.88%||Dividend Payout Ratio|
|Cash From Financing Activities||700 K||Cash From Investing Activities||-54.72 M||Cash From Operating Activities||-18.84 M||Gross Profit|
|Net Profit||-22.27 M||Operating Profit||-22.33 M||Total Assets||274.12 M||Total Current Assets||177.26 M|
|Total Current Liabilities||16.44 M||Total Debt||2.89 M||Total Liabilities||16.6 M||Total Revenue||1.24 M|
|High 52 week||4.5||Low 52 week||1.79||Last close||2.85||Last change||-2.06%|
|RSI||20.45||Average true range||0.2||Beta||1.19||Volume||236.01 K|
|Simple moving average 20 days||-16.23%||Simple moving average 50 days||-19.14%||Simple moving average 200 days||-2.97%|
|Performance Week||-13.64%||Performance Month||-22.76%||Performance Quart||-8.65%||Performance Half||29.55%|
|Performance Year||-34.93%||Performance Year-to-date||10.89%||Volatility daily||3.18%||Volatility weekly||7.11%|
|Volatility monthly||14.56%||Volatility yearly||50.45%||Relative Volume||181.52%||Average Volume||419.6 K|
|New High||New Low|
2020-05-28 08:00:10 | Chimerix to Present at Jefferies Virtual Healthcare Conference
2020-05-12 06:47:02 | Revenue Downgrade: Here's What Analysts Forecast For Chimerix, Inc. NASDAQ:CMRX
2020-05-07 10:25:02 | Chimerix CMRX Reports Q1 Loss, Lags Revenue Estimates
2020-05-07 09:07:00 | Recap: Chimerix Q1 Earnings
2020-05-07 07:00:10 | Chimerix Reports First Quarter 2020 Financial Results and Provides Operational Update
2020-05-02 08:40:26 | One Thing To Remember About The Chimerix, Inc. NASDAQ:CMRX Share Price
2020-03-04 23:36:37 | Edited Transcript of CMRX earnings conference call or presentation 25-Feb-20 1:30pm GMT
2020-02-28 12:00:05 | All You Need to Know About Chimerix CMRX Rating Upgrade to Buy
2020-02-26 08:00:10 | Chimerix to Present at Cowen and Company 40th Annual Health Care Conference
2020-02-25 06:30:00 | Chimerix, Inc. to Host Earnings Call
2020-02-24 08:00:10 | Chimerix Appoints Pratik S. Multani, M.D., to Board of Directors
2020-02-06 07:04:33 | Investors Who Bought Chimerix NASDAQ:CMRX Shares Five Years Ago Are Now Down 96%
2020-02-05 11:52:05 | Steven Cohen Renews His Interest in Verastem
2020-01-03 11:30:04 | Has Chimerix CMRX Outpaced Other Medical Stocks This Year?
2019-12-23 06:12:44 | Here's Why We're Watching Chimerix's NASDAQ:CMRX Cash Burn Situation
2019-12-16 01:04:14 | New Trade Deal, New Records for S&P and NASDAQ
2019-12-14 20:59:21 | Is Chimerix Inc CMRX A Good Stock To Buy?
2019-12-10 07:30:10 | Chimerix Presents Updated Results from Phase 2 Clinical Trial of DSTAT in Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia at American Society of Hematology Annual Meeting
2019-12-04 01:01:26 | Stocks Not Happy About Talk of Trade Deal Delay
2019-11-11 20:58:53 | Edited Transcript of CMRX earnings conference call or presentation 5-Nov-19 1:30pm GMT
2019-11-07 06:19:51 | Should You Be Concerned About Chimerix, Inc.'s NASDAQ:CMRX Historical Volatility?
2019-11-05 07:00:00 | Chimerix Announces Third Quarter 2019 Financial Results and Provides Operational Update
2019-11-04 16:01:00 | Chimerix to Present at Upcoming Investor Conferences
2019-10-02 08:47:45 | Have Insiders Been Buying Chimerix, Inc. NASDAQ:CMRX Shares?
2019-09-27 08:00:00 | Chimerix to Present at 2019 Cantor Global Healthcare Conference
2019-08-08 09:35:01 | Chimerix CMRX Reports Q2 Loss, Lags Revenue Estimates
2019-08-08 08:00:00 | Chimerix Announces Second Quarter 2019 Financial Results and Operational Update
2019-08-07 10:30:02 | Chimerix CMRX Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
2019-08-05 07:55:16 | Durham pharma spends $30 million for rights to potential Leukemia treatment
2019-07-12 15:07:33 | Do Institutions Own Chimerix, Inc. NASDAQ:CMRX Shares?
2019-06-28 18:41:45 | Did Hedge Funds Drop The Ball On Chimerix Inc CMRX ?
2019-05-16 09:11:01 | Will Chimerix to Surge Higher?
2019-05-09 14:08:22 | Edited Transcript of CMRX earnings conference call or presentation 9-May-19 12:30pm GMT
2019-05-09 09:25:01 | Chimerix CMRX Reports Q1 Loss, Tops Revenue Estimates
2019-05-09 08:25:59 | Chimerix: 1Q Earnings Snapshot
2019-05-09 08:00:00 | Chimerix Announces First Quarter 2019 Financial Results and Strategy Update
2019-05-09 06:30:00 | Chimerix, Inc. to Host Earnings Call
2019-05-02 16:01:00 | Chimerix to Announce First Quarter 2019 Financial Results on May 9, 2019
2019-04-29 10:31:02 | Will Chimerix CMRX Report Negative Q1 Earnings? What You Should Know